The integration of artificial intelligence in healthcare, particularly in oncology, has been significant, with new AI tools being recommended in clinical guidelines. However, a study led by urology resident David-Dan Nguyen at the University of Toronto has uncovered a troubling lack of transparency regarding industry payments to healthcare providers. Analyzing the Open Payments database, the research found that fewer than 10% of nearly 850 AI devices authorized by the FDA were linked to any reported payments from manufacturers between 2017 and 2023. This raises critical questions about the potential influence of financial relationships on the adoption of AI technologies in clinical practice and the ethical considerations surrounding patient care. The findings underscore the need for clearer reporting requirements to ensure transparency in the health tech industry.